Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of its lead asset, MT-601, in patients with metastatic pancreatic cancer.